Proactive Investors ‘ReNeuron provides encouraging update to phase II eye disease trial’
Proactive Investors ‘ReNeuron Group’s phase IIb stroke trial kicks off with first patient treated’
Proactive Investors : “ReNeuron signs exosome collaboration deal with US biopharma”
OIS: Ophthalmology Innovation & Investment – ReNeuron using hRPCs to treat inherited retinal degenerative diseases
Interim Results for the six months ended 30 September 2018
14 December 2018: To log on to view a recording of the webcast of the analyst presentation, please click here.
To view the Interim Results Presentation slides please click here.
CFO presents at the 8th Annual Partnering Forum on the Mesa 2018
AGM Trading Update – Shareholder Presentation
Click here to access the presentation made at the AGM.
Preliminary results for the year ended 31 March 2018
To view the presentation of the preliminary results for the year ended 31 March 2018 please click here.
To access the webcast please click here.
ReNeuron signs retinal stem cell exclusivity agreement
17 May 2018 Capital Markets Event – Exosome Nanomedicine Platform
To access the webcast please click here.
To view the slides presented at the above Capital Markets Event please click here.